Children and teens may qualify for this study if they:
Are between the ages 12-17
Have at least 1 Migraine per month
Have at least 6 Month history of Migraine
Currently, more than half of pediatric/adolescent patients with migraines have 1 to 4 attacks per month, causing interference with their daily activities of life. Although many studies have been done in adults with migraine, doctors continue to research treatment options for migraine in children and teens through clinical studies.
In this study, doctors want to evaluate the safety and efficacy of a dissolving tablet called rimegepant in children and teens 6 to 17 years old. Rimegepant is already approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults.
You and the participant will be asked to attend up to 4 study visits over a period of 19 weeks, inlcuding a 4-week screening period, a 15-week treatment period, and a follow-up visit approximately 7 days after each dose of the study drug. Each study visit will last about 1 - 2 hours.
There is no cost to participate in this study, and no insurance is needed. Study participants will be compensated for enrollment in this study.
Why is this study important?
How long will the study last?
Who is this study for?
The Biohaven Study
The Abbvie Periscope Study
The PERISCOPE Study is evaluating an investigational product for the treatment of migraines in children and adolescents between the ages of 6 to 17. The investigational product is currently approved to treat migraines in adults.
We are inviting you to take part in a clinical study for children and adolescents of 6 to 17 years of age who suffer from migraines. All study - related visits, tests, and investigational products will be provided at no cost. In addition , you may receive compensation for you time and travel. No health insurance is required to participate.
You or your child may qualify for the PERISCOPE Study if you or they:
Are between the ages of 6- 17 years old
Have been experiencing migraines for at least 6 months
Experience between 1 and 4 migraine attacks per month
Be currently taking or have taken at least 1 oral medication (examples include ibuprofen, Tylenol®, aspirin, Excedrin®, or a prescription medication) for the treatment of migraine
Jaclyn Brooks is the Sub-Investigator on the Pediatric/Adolescent Migraine Study at Access Clinical Trials, Inc. In addition to being CEO of the company, Jaclyn is a registered nurse with many years of pediatric clinical experience. Since founding Access Clinical Trials in 1999, she has earned extensive training and certifications in the area of Pediatric Neurology. Jaclyn has conducted numerous Pediatric Neurology Trials since 2007.
Dr. James Fry is the Principal Investigator on the Pediatric/Adolescent Migraine Study at Access Clinical Trials, Inc.. Dr. Fry earned his Doctor of Medicine Degree from Texas Tech Health Science Center in 1985. Since joining Access in 2006 he has obtained extensive training and certifications in various areas of Pediatric Neurology Dr. Fry is a current member of the Child Neurology Society, American Academy of Neurology, Southern Medical association, and the American Headache Society. Contact: Midtown Pediatric Neurology
Carol Arvin, RNC NP is a Sub-Investigator for the Pediatric/Adolescent Migraine Study. Carol has done extensive work with evaluation and treatment protocols of headache management with several neurologists in the Nashville medical community.
Taneka Sullins is the Primary Study Coordinator of the Pediatric/Adolescent Migraine Study at Access Clinical Trials Inc. Taneka is a certified Clinical Medical Assistant, having earned her Associate Degree of Science from Miller Motte Technical College in 2015. She has extensive training in Pediatric Neurology Trials, and works closely with Dr. Fry.